Available Until 10/23/2026
View Cart

Recorded Pharmacist Series: Biomarkers 201: BRCA1 and BRCA2

ACPE Activity Number: 0204-0000-24-540-H01-P
Release Date: October 23, 2024
Expiration Date: October 23, 2026
Activity Type: Knowledge-based
CE Credits:  0.25 contact hours, no partial credit
Activity Fee: Member – Free / Non-Member – Not Available 

Activity Overview 

When the FDA and NIH Biomarker Working Group updated the original 2018 BEST Resource in 2021, the understanding and classification of biomarkers like BRCA1/2 changed. This presentation highlights how these changes affect cancer risk diagnostics and provides a resource for evidence-based application of specific genetic testing in the pharmacist’s clinical practice.

ACPE Provider with Commendation logo

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

This activity was planned to meet the educational needs of pharmacists who may be using the biomarker BRCA1/2 as a part of oncology patient risk assessment to determine treatment.  

After participating in this CPE activity, participants should be able to:

  • Identify the classification of BRCA1/2 and the test process for evaluating mutations as defined by the BEST Resource​.
  • Summarize the use of BRCA1/2 in clinical practice to make treatment decisions for patients with certain cancers​. 

  • Introduction and Announcements 

  • Presentation  

Donald Moore
Clinical Oncology Pharmacy Manager
Atrium Health Levine Cancer
Charlotte, NC 28204  

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

  • No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company. 

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Once you have processed and claimed your CE credit, we encourage you to check your NABP eProfile account to verify your credits were transferred successfully before the ACPE 60-day deadline. It is an electronic direct-report process so your credits should appear in your account within a few minutes. After the 60 day deadline, ASHP will no longer be able to report your credit(s) for this activity.